Efficacy and safety of neoadjuvant targeted therapy in non-small cell lung cancer: a systematic review and meta-analysis.

Syst Rev · 2026 · PMC13094070 · PMID 41821091

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Moreover, third-generation EGFR-TKIs (e.g., osimertinib) showed a trend toward higher ORR and R0 resection rates compared to first- and second-generation agents, though the differences were not statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.